Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.
PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.
Abstract
Objective
To assess late toxicities, cosmesis, and oncological outcomes in patients treated with Partial Breast Irradiation (PBI) using interstitial multi-catheter high dose-rate brachytherapy.
Methods
From 2003 to 2023, 292 patients were enrolled in a prospective observational study (follow-up up to 20 years).
INCLUSION CRITERIA
age ≥40 years; ECOG 0-2; ductal carcinoma in situ; invasive non lobular carcinoma; tumor size ≤2.5 cm; negative axillary lymph nodes; surgical margins ≥2 mm. PBI dose was 32 Gy in 8 fractions over 4 days.
Results
Invasive carcinoma accounted for 92.1% of cases. Late toxicities (mainly telangiectasia, fibrosis, liponecrosis) occurred in 100/286 patients evaluated (35%). Cosmetic outcomes were rated as excellent/good in 96% of cases. Ipsilateral breast tumor recurrence occurred in 10 patients (3.4%) with a 5-year cumulative incidence of 1.8% and 3.8% at 10 and 15 years. Breast cancer-free specific survival was 98.4% after 5 years, 95.7% after 10 years, and 94% after 15 years. Overall survival was 93% after 5 years, 69% after 10 years, and 53.4% after 15 years.
Conclusions
PBI using interstitial multi-catheter high dose-rate brachytherapy is effective and well-tolerated for selected early-stage breast cancer showing excellent long-term toxicity, cosmetic profiles, and outcomes.
PURPOSE
To report long-term oncologic, cosmetic, and toxicity outcomes of permanent breast seed implantation (PBSI) using palladium-103 as accelerated partial breast irradiation (APBI) for early-stage breast cancer.
METHODS AND MATERIALS
This prospective, single-institution study enrolled 27 patients in 2013-2015. Ou...
U. Amit, T. Meyer, M. Roumeliotis et al.· Brachytherapy· 0 citations
Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.
Z. El Kouzi, M. Rooney, Adam B. Samman et al.· Brachytherapy· 0 citations
Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.
E. Ogo, T. Arimura, T. Ogino et al.· Breast Cancer· 0 citations
HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control and the incidence of late grade 3 rectal bleeding requires careful patient selection.
Alexander Kristen, N. Tselis, M. Diefenhardt et al.· Strahlentherapie und Onkolog...· 0 citations
OBJECTIVE
To report long-term outcomes and late toxicity after external beam radiotherapy (EBRT) with single-fraction high-dose-rate brachytherapy boost (HDR-BTB) for localized prostate cancer, examining HDR-BT sequencing and risk stratification.
METHODS AND MATERIALS
We retrospectively analyzed 607 (2012-2023) men t...
M. Choudhury, F. Adeoye, S. Nageshwaran et al.· Brachytherapy· 0 citations
PURPOSE
Although stereotactic body radiotherapy (SBRT) boost represents a promising treatment option for patients with locally advanced cervical cancer who were considered unsuitable for brachytherapy, its long-term efficacy and safety remain unclear. This study assessed long-term oncologic outcomes and late toxicities...
K. Ito, Y. Nakajima, H. Ogawa et al.· Japanese Journal of Radiolog...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.